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Abstract 
Purpose: Neurofilament light (NfL) is a biomarker reflecting neurodegeneration and acute neuronal injury, and 
an increase is found following hypoxic brain damage. We assessed the ability of plasma NfL to predict outcome in 
comatose patients after out-of-hospital cardiac arrest (OHCA). We also compared plasma NfL concentrations between 
patients treated with two different targets of arterial carbon dioxide tension  (PaCO2), arterial oxygen tension  (PaO2), 
and mean arterial pressure (MAP).
Methods: We measured NfL concentrations in plasma obtained at intensive care unit admission and at 24, 48, and 
72 h after OHCA. We assessed neurological outcome at 6 months and defined a good outcome as Cerebral Perfor-
mance Category (CPC) 1–2 and poor outcome as CPC 3–5.
Results: Six-month outcome was good in 73/112 (65%) patients. Forty-eight hours after OHCA, the median NfL 
concentration was 19 (interquartile range [IQR] 11–31) pg/ml in patients with good outcome and 2343 (587–5829) 
pg/ml in those with poor outcome, p < 0.001. NfL predicted poor outcome with an area under the receiver operating 
characteristic curve (AUROC) of 0.98 (95% confidence interval [CI] 0.97–1.00) at 24 h, 0.98 (0.97–1.00) at 48 h, and 0.98 
(0.95–1.00) at 72 h. NfL concentrations were lower in the higher MAP (80–100 mmHg) group than in the lower MAP 
(65–75 mmHg) group at 48 h (median, 23 vs. 43 pg/ml, p = 0.04).  PaCO2 and  PaO2 targets did not associate with NfL 
levels.
Conclusions: NfL demonstrated excellent prognostic accuracy after OHCA. Higher MAP was associated with lower 
NfL concentrations.
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Introduction
Many patients resuscitated from out-of-hospital cardiac 
arrest (OHCA) suffer from hypoxic–ischaemic brain 
injury (HIBI) and die in the intensive care unit (ICU) 
without regaining consciousness [1, 2]. Accurate prog-
nostication is of paramount importance to prevent pro-
longed futile intensive care and, on the other hand, to 
avoid withdrawal of care in those who have a chance to 
recover [3, 4]. Current guidelines recommend a multi-
modal approach in the prognostication of cardiac arrest 
(CA) patients including clinical examination, radiological 
imaging, neurophysiological assessment, and biomarkers 
[5]. Unfortunately, some of these methods are not univer-
sally available [6, 7] and others can be affected by sedative 
medication and muscle paralysis often needed with tar-
geted temperature management (TTM) [8].
Blood biomarkers are considered potential tools for 
prognostication because they are easy to obtain, and the 
results are not affected by the use of medication. Cur-
rently, neuron-specific enolase (NSE) is the most widely 
used biomarker in cardiac arrest (CA) patients [5]. NSE 
concentration at 48–72  h after CA has demonstrated 
moderate accuracy with areas under the receiver oper-
ating characteristic curves (AUROC) between 0.85 and 
0.90 in predicting neurological outcome, but optimal cut-
off values vary widely between studies [9–12]. Unfortu-
nately, NSE is sensitive to blood sample haemolysis [13] 
and its prognostic ability is reduced in the elderly and in 
patients with shorter CA duration [14]. Therefore, novel 
biomarkers with superior performance to predict neu-
rological outcome after OHCA are urgently needed to 
guide clinical management of this group of patients. Neu-
rofilament light (NfL) is a 68 kD cytoskeletal neuron-spe-
cific protein showing high promise as a clinically useful 
biomarker for acute brain conditions such as traumatic 
brain injury [15]. Recently, serum NfL was also shown 
to have excellent prognostic accuracy at 24–72  h from 
CA [16], but further external validation in independent 
patient cohorts is required before the routine use of NfL 
can be incorporated into clinical practice.
In the Carbon dioxide, Oxygen and Mean arte-
rial pressure After Cardiac Arrest and REsuscitation 
(COMACARE) trial, we recently showed that target-
ing high-normal or low-normal carbon dioxide tension 
 (PaCO2), normoxia or moderate hyperoxia, and low-
normal or high-normal mean arterial pressure (MAP) 
did not affect NSE concentrations in comatose OHCA 
patients [17, 18]. Given the possible superior prognos-
tic accuracy of NfL and its different sensitivity to axonal 
brain injury, we performed a post hoc sensitivity analysis 
and measured NfL concentrations in patients included in 
the COMACARE trial. We hypothesised first that com-
pared to NSE, NfL would be an earlier and more accurate 
biomarker of neurological outcome and that targeting 
high-normal  PaCO2, moderate hyperoxia, and, second, 
high normal MAP would result in lower levels of NfL 
when compared with the lower targets.
Methods
Study population and research approvals
The COMACARE trial (NCT02698917) was a prospec-
tive, randomised pilot study of 120 comatose OHCA 
patients resuscitated from an initial shockable rhythm. 
The trial was a  23 factorial trial exploring the effects of 
low-normal vs. high-normal arterial carbon dioxide ten-
sion (4.5–4.7 vs. 5.8–6.0  kPa), normoxia vs. moderate 
hyperoxia (arterial oxygen tension 10–15 vs. 20–25 kPa) 
and low-normal vs. high-normal mean arterial pressure 
(65–75 vs. 80–100 mmHg) for 36 h post-resuscitation on 
markers of neurological damage, assessed primarily with 
neuron-specific enolase (NSE) concentrations in serum 
at 48 h after cardiac arrest. The study was conducted in 
seven ICUs in Finland and Denmark between March 
2016 and November 2017. Randomisation was stratified 
according to TTM (33  °C or 36  °C, according to site-
specific protocols). Neurological prognostication was 
performed according to European Resuscitation Council 
and European Society of Intensive Care Medicine guide-
lines [19]. The study protocol and the main results have 
been published previously [17, 18, 20]. In the current 
post hoc analysis, we measured the NfL concentrations in 
the blood samples of 112 Finnish patients included in the 
COMACARE trial. The original COMACARE study pro-
tocol was approved by the Ethics committee of Northern 
Savo Hospital District, Finland (decision no. 295/2015), 
and an amendment including the plan for the current 
analysis was approved in December 2017.
Data collection
We obtained blood samples at the time of ICU admis-
sion (0  h) and 24, 48, and 72  h after CA. The samples 
were centrifuged (2000 G, 10 min) and stored at − 70 °C 
for later analysis. Plasma NfL concentration was meas-
ured using the commercially available Single Molecule 
Array (Simoa) NF-Light immunoassay (Quanterix, Bill-
erica, MA, United States) in the Clinical Neurochemistry 
Laboratory of the University of Gothenburg (Mölndal, 
Sweden) in September 2019. Staff who conducted the 
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analysis were blinded to all clinical data. The samples 
were diluted fourfold, and a single batch of reagents was 
utilised for all eight analytical runs needed to complete 
the analyses. For the low-concentration control sample 
(LCS; 6.9 ng/l), the intra-assay coefficient of variation was 
7.4% and the inter-assay coefficient of variation was 8.9%, 
whilst for the high concentration quality control sample 
(HCS; 55.1 ng/l), the corresponding coefficients of varia-
tion were 7.1% and 10.4%, respectively.
Serum NSE concentration was measured using a 
COBAS e601 line (Hitachi High Technology Co, Tokyo, 
Japan) with an electrochemiluminescent immunoassay 
kit (Roche Diagnostics GmbH, Mannheim, Germany) 
by ISLAB laboratories (Kuopio, Finland) in January 
2018.  Because haemolysis can significantly affect NSE 
results, all samples were tested using the Roche haemoly-
sis index, and the samples with a haemolysis level of more 
than 500 mg of free haemoglobin per litre were excluded 
from the analyses [21].
Patient data regarding comorbidities, functional status, 
and resuscitation-associated factors were collected into 
an Internet-based database (Absolute Imaginary Soft-
ware, Helsinki, Finland). A neurologist blinded to the 
results of the laboratory analysis, study group allocations, 
and treatment during hospital stay evaluated the neu-
rological outcome using the Cerebral Performance Cat-
egory (CPC) scale at six months after CA via a telephone 
interview. We considered CPC 1–2 as good outcome and 
CPC 3–5 as poor outcome.
Statistical analysis
We present categorical variables as counts and percent-
ages, including 95% confidence intervals (CI) where 
applicable, and continuous variables as medians and 
interquartile ranges (IQR). We compared categorical 
variables with Pearson’s Chi squared test or Fisher’s exact 
test. We tested the normality of distribution of continu-
ous variables with the Kolmogorov–Smirnov test and 
then compared normally distributed variables using the 
independent samples t test, and non-normally distrib-
uted variables using the Mann–Whitney U test or the 
Kruskal–Wallis test.
We assessed the ability of NfL and NSE to predict 
poor neurological outcome at 6  months by calculat-
ing the area under the receiver operating characteristic 
curve (AUROC). We compared the discriminative abil-
ity of NfL and NSE by comparing their AUROC values 
at ICU admission and at 24, 48 and 72 h after CA with 
a bootstrap method. The used bootstrap function is 
within the roc.test function (R program, https ://www.
rdocu menta tion.org). We assessed optimal cutoff values 
for NfL at 24–72 h after CA from the receiver operating 
characteristic curves (ROC). Because high specificity is 
important in prognostication, we assessed cutoff val-
ues with a specificity higher than 95%. In addition, we 
determined cutoff values with the Youden method [22, 
23]. We also determined the sensitivity, specificity, pos-
itive (PPV) and negative predictive values (NPV), and 
positive likelihood ratios (LR +) for these cutoff values. 
We also report cutoff values for the prediction of good 
functional outcome with high specificity and sensitivity.
To predict poor 6-month neurological outcome, 
we created a multivariable model, including patient 
age, receipt of bystander-given basic life support, and 
the time from collapse to the return of spontaneous 
circulation (ROSC). We then added NfL concentra-
tions measured at 24, 48, and 72 h into this model and 
assessed the improvement of prognostic accuracy by 
comparing the AUROCs between the baseline model 
and the models after the addition of NfL. We also cal-
culated the Net Reclassification Improvement (NRI) 
achieved with the addition of NfL into the baseline 
model. Event NRI (NRIe) is calculated as [(the number 
of patients with poor outcome for whom the predicted 
probability of poor outcome increases with addition of 
NfL to the baseline prediction model) −   (the number 
of patients with poor outcome for whom the predicted 
probability decreases)]/[the number of all patients with 
poor outcome]. Similarly, non-event NRI (NRIne) is the 
net proportion of patients with good outcome given a 
lower probability of poor outcome after addition of NfL 
to the baseline prediction model. The overall NRI is the 
sum of NRIe and NRIne. The theoretical range of values 
for both NRIe and NRIne is − 1 to + 1, and the range of 
values for overall NRI is – 2 to + 2 [24, 25].
In addition, we determined the integrated discrimi-
nation improvement (IDI) that was obtained by add-
ing NfL into the baseline prediction model. Event IDI 
(IDIe) is calculated for patients with poor outcome 
as [(mean probability of poor outcome given by the 
model including NfL) − (mean probability of poor out-
come given by the baseline model)] and non-event IDI 
(IDIne) for patients with good outcome as [(mean prob-
ability of poor outcome given by the baseline model) − 
(mean probability of poor outcome given by the model 
including NfL)]. IDI is the sum of IDIe and IDIne. The 
theoretical range of values for both IDIe and IDIne is 
− 1 to + 1, and the range of values for IDI is – 2 to + 2 
[25, 26].
We conducted all statistical analyses with SPSS (SPSS, 
Chicago, IL, USA) version 25.0 and R version 3.5.1. We 
used two-tailed p values with the level of significance set 
at a p value less than 0.05, and made no correction to the 
p value despite the multiple testing.
Results
Blood samples for NfL analysis were available for 112 
of the 120 patients included in the COMACARE trial 
(Fig.  1). The baseline characteristics and resuscitation-
associated factors are presented in Table  1. All patients 
were unconscious on arrival to the ICU and treated with 
TTM either in 33 °C or 36 °C. The 6-month neurological 
outcome was poor in 39 (35%) patients, with 37 deaths 
(33%) and two patients recovering to CPC 3. In 32 (86%) 
of the deceased, the cause of death was HIBI. The investi-
gations used to determine the prognosis in patients with 
a poor functional outcome are shown in the Electronic 
Supplementary Material (ESM) (Tables S1). 
Prognostic accuracy of NfL
NfL concentrations were significantly higher in patients 
with poor outcome than in those with good outcome at 
all studied time points (Table 2, Fig. 2). The difference in 
NfL concentration between patients with poor and those 
with good outcome was at its greatest 48 h after cardiac 
arrest, when the median (IQR) NfL concentrations were 
2343 (587–5829) pg/ml and 19 (11–31) pg/ml, respec-
tively (p < 0.001). 
The ability of NfL to discriminate patients with poor 
outcome from those with good outcome was excellent 
at 24, 48, and 72  h after CA with AUROC values of 
0.98 (95% CI 0.97–1.00), 0.98 (95% CI 0.97–1.00), and 
0.98 (95% CI 0.95–1.00), respectively (Fig. 3). The NfL 
concentration at ICU admission had a poor prognos-
tic ability with an AUROC of 0.66 (95% CI 0.54–0.77), 
which was clearly inferior compared to the AUROCs 
of NfL concentrations at 24, 48 and 72  h after CA 
(p < 0.001). NfL had an excellent ability to predict death 
from HIBI (ESM, Fig. S1). There was no difference in 
the prognostic accuracy of NfL depending on TTM tar-
get used during ICU care (ESM, Fig. S2).
NfL compared with NSE and S100B
Compared with NSE, NfL had a markedly better ability 
to discriminate patients with poor outcome from those 
with good outcome (p < 0.001 for measurements at 24 
and 48 h; p = 0.012 at 72 h]) (Fig. 3). NfL was also bet-
ter than S100B to discriminate between patients with 
good outcome and those with poor outcome at 24–72 h 
(p < 0.001) (Fig.  3). At ICU admission, the prognos-
tic performance of NfL was poor, and the AUROCs 
were not significantly different between  NfL and NSE 
(p = 0.185) and NfL and S100B (p = 0.767) (Fig. 3).
Cutoff values
The cutoff values at 24, 48 and 72  h after CA for 
obtaining a specificity of 99% in predicting poor out-
come were 127, 263, and 344  pg/ml, respectively. The 
corresponding sensitivities and positive and nega-
tive predictive values are presented in Table  2. Cutoff 
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Fig. 1 Flowchart of the study population. ICU intensive care unit
values determined according to the Youden method 
and according to specificities of 95–100%, together 
with the corresponding sensitivities and positive and 
negative predictive values are presented in the ESM 
(Table  S2). Cutoff values for identification of patients 
with good functional outcome are presented in the 
ESM (Table S3).
NfL and clinical prognostication data
The baseline multivariable model predicted a poor 
6-month outcome with an AUROC of 0.86 (95% CI 
0.79–0.93) (Table  S4). After NfL concentration at 24  h 
was added to this model, the AUROC improved to 0.98 
(0.97–1.00), p < 0.001. After adding NfL concentra-
tion at 48  h, the AUROC increased to 0.99 (0.98–1.00) 
(p < 0.001), and after adding NfL concentration at 72  h, 
the AUROC was 0.99 (0.98–1.00) (p < 0.001). With the 
Table 1 Baseline characteristics of the study patients
CPC Cerebral Performance Category, IQR interquartile range, NYHA New York Heart Association, ROSC return of spontaneous circulation, ICU intensive care unit, GCS 
Glasgow Coma Scale, SD standard deviation, APACHE II Acute Physiology and Chronic Health Evaluation
a Data missing for two patients
b Data missing for 13 patients
c Data missing for nine patients
All patients (N = 112) CPC 1–2 (N = 73) CPC 3–5 (N = 39) p value
Age, median (IQR) (years) 62 (53–68) 58 (51–66) 66 (58–75) 0.004
Male sex [n (%)] 92 (82.1) 61 (83.6) 31 (79.5) 0.592
Weight [median (IQR), kg] 85 (72.3–93) 85 (72.5–94) 83 (70–90) 0.646
Neurological function before cardiac arrest
 Normal, CPC 1 [n (%)] 103 (92) 67 (91.8) 36 (92.3) 1
 Some disability, CPC 2 [n (%)] 9 (8) 6 (8.2) 3 (7.7)
Medical history
 Hypertension [n (%)] 56 (50) 33 (45.2) 23 (59) 0.165
 Chronic heart failure (NYHA 3 or 4) [n (%)]ª 9 (8) 4 (5.5) 5 (12.8) 0.151
 Smoker [n (%)]b 35 (31.3) 22 (30.1) 13 (33.3) 0.235
Resuscitation factors
 Bystander life support [n (%)] 93 (83) 66 (90.4) 27 (69.2) 0.004
 Time to ROSC [median (IQR), min] 21 (16–26) 17 (15–22) 25 (22–32) < 0.001
Clinical status on ICU admission
 GCS [median, (IQR)]c 3 (3–3) 3 (3–5) 3 (3–3) < 0.001
 APACHE II score, median (IQR) 28 (24–31) 27 (24–29) 31 (26–35) < 0.001
TTM
 33 °C [n (%)] 75 (67) 56 (76.7) 19 (48.7) 0.003
 36 °C [n (%)] 37 (33) 17 (23.3) 20 (51.3)
Table 2 NfL concentrations (medians with  IQRs) at  ICU admission and  24, 48 and  72  h after  cardiac arrest for  patients 
with  good outcome (CPC 1–2) and  for those with  poor outcome (CPC 3–5), and  cutoff values with  sensitivities, PPVs 
and NPVs at 24–72 h according to 99% of specificity
CPC Cerebral Performance Category, NfL neurofilament light, IQR interquartile range, ICU intensive care unit, PPV positive predictive value, NPV negative predictive 
value, CI confidence interval
NfL concentration pg/ml (IQR) Cutoff for 99% specificity
Time CPC 1–2 CPC 3–5 p value NfL pg/ml Sensitivity PPV (95% CI) NPV (95% CI) p 
value
ICU admission 10.4 (7.1–16) 13.4 (10.5—23.2) 0.002
24 h 12.1 (8.3–23.7) 761.9 (217.6–1534.9) < 0.001 127 0.78 (0.65–0.92) 0.97 (0.90–1.00) 0.90 (0.83–0.96) < 0.001
48 h 19.1 (11–30.7) 2342.6 (586.9–5828.8) < 0.001 263 0.83 (0.71–0.96) 0.97 (0.91–1.00) 0.92 (0.86–0.98) < 0.001
72 h 20.5 (13.8–34.8) 1727.9 (643.1–4583.5) < 0.001 344 0.85 (0.73–0.97) 0.97 (0.90–1.00) 0.93 (0.88–0.99) < 0.001
inclusion of NfL to the baseline model at 24 h, NRI was 
1.51 (95% CI 1.24–1.79); at 48 h, NRI was 1.78 (95% CI 
1.58–1.97); and at 72  h, NRI was 1.74 (1.53–1.94). The 
corresponding IDI values were 0.41 at 24 h, 0.45 at 48 h, 
and 0.45 at 72 h (ESM, Table S4).
Haemolysis
Detectable haemolysis (more than 100 mg of free haemo-
globin per litre) was observed in 157 (35%) of all samples. 
Haemolysis did not increase NfL concentrations, whereas 
NSE concentrations were markedly higher in samples 
with haemolysis (ESM, Table S5, Figs. S3 and S4).
NfL concentrations according to carbon dioxide, oxygen, 
and blood pressure targets
There were no significant differences in NfL concentra-
tions between the groups targeting low-normal or high-
normal  PaCO2 and normoxia or moderate hyperoxia at 
any of the studied time points (ESM Table S7). In patients 
assigned to the high-normal MAP group, NfL concentra-
tions were lower than in patients in the low-normal MAP 
group at 48 h (median 23 [IQR 11–251] pg/ml vs. 43 [19–
1066] pg/ml, [p = 0.04]) and at 72 h (23 [13–152] pg/ml 
vs 63 [21–1609] pg/ml [p = 0.007]) (ESM Table S6). NfL 
levels according to outcome in all intervention groups are 
presented in the ESM (Figs. S5–S7).
Discussion
Our findings provide evidence of the excellent abil-
ity of NfL to predict long-term neurological outcomes 
in a homogenous population of cardiac arrest patients 
resuscitated from a shockable rhythm and treated with 
TTM. Moreover, the results of this post hoc analysis offer 
additional  information on the effects of carbon diox-
ide, oxygen, and blood pressure on the development of 
neurological injury after OHCA [17, 18]. Using NfL as 
a marker of neurological injury, we found that a higher 
MAP target of 80–100 mmHg was associated with lower 
NfL levels when compared with the conventional target 
of MAP 65–75  mmHg. We did not observe any signifi-
cant difference in the NfL concentrations between the 
groups targeting low-normal and high-normal  PaCO2, or 
normoxia and moderate hyperoxia.
The predictive accuracy of NfL observed in the current 
study is well in line with the findings of a previous study 
based on the TTM trial [16], whereas the cutoff values in 
our study were much lower. The patient populations in 
these two studies were different. The TTM trial included 
patients without any age limit and included patients with 
a non-shockable initial rhythm, whereas the COMAC-
ARE trial only included patients younger than 80 years, 
with a shockable initital rhythm and patients with time 
to ROSC less than 45 min. Moreover, in the current study 
we have used a new commercially available kit for meas-
uring NfL, while the Moseby-Knappe study used a cus-
tom-made assay [27, 28].
Fig. 2 Scatter plots and box plots presenting neurofilament light (NfL) concentrations at intensive care unit admission (0 h) and 24, 48 and 72 h 
after cardiac arrest for patients with good outcome (Cerebral Performance Category [CPC] 1–2) and those with poor outcome (CPC 3–5) with a 
10-based logarithmic scale. Dots present concentrations for individual patients. Each box depicts the interquartile range, the line inside the box 
shows the median value, and the whiskers show the range of values
The AUROC values of NfL are very high at 24 h from 
CA. This level of accuracy has not been demonstrated 
for any other neurological biomarker [1], and our results 
reinforce the superiority of NfL compared to NSE [16]. 
One possible explanation for this can be the different dis-
tribution of these biomarkers in the grey and white mat-
ter of the brain. NSE is a neuronal enzyme that is more 
abundant in the grey matter [29]. NfL, in contrast, is a 
structural protein that can be found especially in large 
axons in the white matter [30]. Interestingly, radiologi-
cal studies have suggested that white matter is particu-
larly susceptible to ischaemic damage and that the extent 
of white matter injury seems to be associated with CA 
outcome [31]. In addition, it needs to be recognized that 
NSE, S100B and NfL have very different half-lives and 
this will influence the time trajectory of these biomarkers 
in brain injury patients [15]. The very long half-life of NfL 
may explain why it appeared, in contrast with NSE, to 
rise in the patients with good functional outcome as well.
Thus far, no biomarkers can reliably predict the out-
come of OHCA patients at the time of hospital admission 
[1]. In the current study, we observed that the NfL levels 
at the time of admission were slightly higher in patients 
with poor outcome, but because of considerable overlap, 
this is not likely to be useful in clinical practice. At later 
time points, high NfL concentrations were predictive of 
Fig. 3 Receiver operating characteristic curves and areas under the curves (AUROC) with 95% confidence intervals (CI) for NfL, NSE and S100B at 
intensive care unit (ICU) admission and 24, 48 and 72 h after cardiac arrest, presenting these biomarkers’ ability to discriminate between patients 
with good outcome (Cerebral Performance Category [CPC] 1–2) and those with poor outcome (CPC 3–5) at six months. NfL neurofilament light, NSE 
neuron-specific enolase
poor outcome: no patients with concentrations higher 
than 390  pg/ml at any time point had a good outcome. 
However, our study population is too small to enable a 
threshold value to be proposed for prognostication.
One of the known limitations of NSE is that even 
mild haemolysis in the sample can result in erroneously 
elevated NSE levels [13]. Haemolysis is especially com-
mon in patients receiving continuous renal replacement 
therapy, intra-arterial balloon pump support, or extra-
corporeal membrane oxygenation, which are not uncom-
mon interventions after OHCA. Importantly, the study 
by Moseby-Knappe et  al. did not show any association 
between the level of haemolysis and NfL concentrations 
[16]. Our study also suggests that haemolysis does not 
influence NfL concentrations. Other conditions such as 
amyotrophic lateral sclerosis, HIV-associated dementia, 
and extensive traumatic brain injury (TBI) can affect NfL 
levels, but they are very uncommon in OHCA patients 
[16].
This additional analysis of the COMACARE trial shows 
an association between higher MAP and lower NfL con-
centrations, which may reflect the degree of brain injury. 
Given the small sample size and the post hoc design of 
the current study, this finding should be interpreted 
with caution and considered as hypothesis generating. 
Moreover, the absolute difference in NfL concentrations 
between the different MAP groups was small when com-
pared with the 100-fold difference between the patients 
with good and poor outcomes. The possible beneficial 
effect of the higher MAP on clinical outcomes may be 
small compared to other factors, such as age, delay in 
resuscitation, and ROSC, and larger randomised trials 
are needed before the optimal blood pressure target after 
OHCA can be defined. Regarding carbon dioxide and 
oxygen, the results of the additional NfL analyses of the 
current study support the neutral results of the COMAC-
ARE trial on NSE.
Strengths and limitations
The current study has several strengths. First, the NfL 
results were not available to clinicians during patient care 
and could thus not have influenced treatment decisions. 
Second, the NfL concentrations were measured concur-
rently by the same laboratory. Third, we studied patients 
treated in multiple centres with TTM at both 33 °C and 
36 °C.
A major limitation of the current study is the relatively 
small sample size. Moreover, our patient cohort was 
rather selected, including only patients with witnessed 
cardiac arrest with a shockable initial rhythm from a 
presumed cardiac origin and with time from collapse to 
ROSC between 15 and 45 min. Future studies are needed 
to clarify the accuracy of NfL in unselected patient 
populations. The analysis was conducted in frozen sam-
ples, but the evidence suggests the stability of NfL in 
freeze–thaw samples [32]. Regarding the effect of carbon 
dioxide, oxygen, and MAP on NfL levels after OHCA, we 
acknowledge that the current study was designed post 
hoc, increasing the possibility of chance findings.
Conclusions
In unconscious OHCA patients treated with TTM, NfL 
had excellent prognostic accuracy already at 24 h. Com-
pared to NSE, NfL seems to be a more accurate bio-
marker for prognostication after CA, and if validated in 
further samples, it has potential to replace NSE in the 
multimodal prognostication algorithms. Targeting a 
higher MAP of 80–100 mmHg was associated with lower 
levels of NfL, generating a hypothesis that higher blood 
pressure after CA could attenuate brain injury.
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